These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32680595)

  • 21. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
    Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
    Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus.
    Tsuchiya T; Ishida H; Tanabe T; Shimizu T; Honda K; Omoto K; Tanabe K
    Transplantation; 2013 Jul; 96(2):198-204. PubMed ID: 23792649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients.
    Guirado L; Cantarell C; Franco A; Huertas EG; Fructuoso AS; Fernández A; Gentil MA; Rodríguez A; Paul J; Torregrossa JV; Rodríguez A; Alonso A; Hernández D; Burgos D; Jiménez C; Jimeno L; Lauzurica R; Mazuecos A; Osuna A; Plumed JS; Ruiz JC; Zárraga S;
    Am J Transplant; 2011 Sep; 11(9):1965-71. PubMed ID: 21668633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients.
    Wu SW; Tsai HC; Tsai PY; Hung TW; Chang HR; Lian JD
    Swiss Med Wkly; 2013; 143():w13850. PubMed ID: 23986367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups.
    Bunnapradist S; Rostaing L; Alloway RR; West-Thielke P; Denny J; Mulgaonkar S; Budde K
    Transpl Int; 2016 May; 29(5):603-11. PubMed ID: 26953629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review.
    Ho ET; Wong G; Craig JC; Chapman JR
    Transplantation; 2013 May; 95(9):1120-8. PubMed ID: 23542469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Favorable longterm outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: Results of a single-center cohort.
    Gastaca M; Valdivieso A; Bustamante J; Fernández JR; Ruiz P; Ventoso A; Testillano M; Palomares I; Salvador P; Prieto M; Montejo M; Suárez MJ; de Urbina JO
    Liver Transpl; 2016 Oct; 22(10):1391-400. PubMed ID: 27434676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: A randomized prospective study.
    Kim JM; Kwon CH; Joh JW; Sinn DH; Lee S; Choi GS; Lee SK
    Liver Transpl; 2016 Feb; 22(2):209-16. PubMed ID: 26360125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation.
    Kolonko A; Chudek J; Wiecek A
    Transplant Proc; 2011 Oct; 43(8):2950-3. PubMed ID: 21996198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.
    Budde K; Bunnapradist S; Grinyo JM; Ciechanowski K; Denny JE; Silva HT; Rostaing L;
    Am J Transplant; 2014 Dec; 14(12):2796-806. PubMed ID: 25278376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Effectiveness of Conversion From Cyclosporine to Once-Daily Prolonged-Release Tacrolimus in Stable Kidney Transplant Patients: A Multicenter Observational Study in Japan.
    Usuki S; Uno S; Sugamori H; Tanaka H; Aikawa A
    Transplant Proc; 2018 Dec; 50(10):3266-3274. PubMed ID: 30577196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once- vs Twice-Daily Tacrolimus: Survival Rates and Side Effects: Single-Center Experience.
    Turunc V; Ari E; Guven B; Tabendeh B; Yildiz A
    Transplant Proc; 2019 Sep; 51(7):2308-2311. PubMed ID: 31400977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
    Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
    Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.
    Lehner LJ; Reinke P; Hörstrup JH; Rath T; Suwelack B; Krämer BK; Budde K; Banas B
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29052906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial.
    Bunnapradist S; Ciechanowski K; West-Thielke P; Mulgaonkar S; Rostaing L; Vasudev B; Budde K;
    Am J Transplant; 2013 Mar; 13(3):760-9. PubMed ID: 23279614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation: randomized controlled trial in adult renal transplantation.
    Oh CK; Huh KH; Lee JS; Cho HR; Kim YS
    Yonsei Med J; 2014 Sep; 55(5):1341-7. PubMed ID: 25048494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.